Novo Nordisk CEO Defends Obesity Drugs

This is a U.S. news story, published by Yahoo, that relates primarily to Novo Nordisk news.

U.S. news

For more U.S. news, you can click here:

more U.S. news

Novo Nordisk news

For more Novo Nordisk news, you can click here:

more Novo Nordisk news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo news

For more news from Yahoo, you can click here:

more news from Yahoo

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

drug costs

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug companies news, weight loss drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Novo Nordisk

NBC News

•

Ozempic maker defends high U.S. price: It’s ‘helping’ reduce the cost of obesity

Summary

Nutrition label

80% Informative

Novo Nordisk CEO Lars Fruergaard Jørgensen says Ozempic and Wegovy are saving taxpayers money on obesity-related costs.

He is scheduled to testify about the U.S. pricing of the drugmaker’s hugely popular diabetes and weight loss drugs at a Senate hearing next month .

Sen. Bernie Sanders , I-Vt., chair of the Health, Education , Labor and Pensions Committee , said he plans to ask Jørgen why the company charges up to 15 times more than it does in other countries.

Cynthia Cox , a vice president at KFF and the director of its program on the Affordable Care Act , said that while the drugs can prevent and reduce a number of obesity-related diseases, they remain expensive and that it’s unclear how long people will need to stay on them to maintain weight loss and improved health. “The widespread use of these drugs for weight loss is still relatively new, so I’m not sure there is enough long-term data to fully weigh the costs and benefits,” Cox said. This article was originally published on NBCNews.com .

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity

Offensive language

possibly offensive

Hate speech

not hateful